The United Kingdom and the United States have forged a significant commercial pact that will preserve no tariffs on UK pharmaceutical exports entering the American market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has pledged to boost spending on drugs through the public health system. This pledge guarantees that import taxes on these key goods will remain at nothing for a period of three years.
This agreement comes after previous statements to hike duties on branded drug imports, with potential rates discussed as high as double the cost.
"This arrangement between the United Kingdom strengthens the global environment for new treatments and brings long-overdue balance to U.S.–U.K. pharmaceutical trade," a release said.
Economic Impact
Medicines constitute one of the Britain's most significant goods shipped to the United States, which is easily the largest market for leading UK drugmakers.
Statistics indicate that in the 12 months to the end of last September, the UK shipped pharmaceutical products totaling £11.1bn to the US. This figure represented a significant portion of British export trade in that span.
"This deal secures employment, boosts funding and paves the way for the UK to emerge as a international leader for medical research," the Business and Trade Secretary stated.
Specific UK Commitments
The agreement entails several notable changes from the United Kingdom:
- Price Threshold Increase: The UK will lift the price threshold at which it judges new treatments to be unaffordable by a quarter.
- Increased NHS Spending: There is a goal to double overall health service expenditure on drugs from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The percentage drug companies must refund to the NHS to control costs will be capped at 15%. Last year, rebates exceeded 20%.
Industry Background
The pact follows a long-running tension between the pharmaceutical industry and the British authorities over medicine costs and NHS adoption.
The disagreement were exacerbated by claims that American consumers were paying significantly more for the identical medicines than people in the Britain and the EU.
In recent months, several significant manufacturing plans in the UK have been halted or abandoned, while multi-billion-dollar investments have been announced toward US facilities.
A senior figure acknowledged that the NHS must invest a greater share on drugs, noting that its expenditure on drugs had shrunk as a share of its resources over the past decade.
